title: Lorcaserin for the treatment of obesity.
abstract: Obesity is a worldwide epidemic and there is an urgent need for the development of effective pharmacological therapies that target the metabolic and behavioral factors of body weight regulation. Serotonin (5-HT) has been implicated as a critical factor in the short-term (meal-by-meal) regulation of food intake and pharmaceutical companies have invested millions of dollars to discover and develop drug targets for the serotonergic pathway. Lorcaserin is a novel selective agonist of the 5-HT(2C) receptor for weight loss therapy. Preclinical and clinical studies indicate lorcaserin is well tolerated and not associated with cardiac valvulopathy or pulmonary hypertension suggesting that lorcaserin is a selective 5-HT(2C) receptor agonist and has little or no activation of the 5-HT(2B) and 5-HT(2A) receptors, respectively. Lorcaserin acts to alter energy balance through a reduction in energy intake and without an increase in energy expenditure and achieved the U.S. Food and Drug Administration guidelines for weight loss efficacy. It remains to be determined whether or not lorcaserin will be approved for the long-term management of obesity.
authors: Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA. leanne.redman@pbrc.edu
authors: L M
authors: LM
authors: Redman
authors: E
authors: E
authors: Ravussin
references: Am J Clin Nutr. 1991 Aug;54(2):321-5
references: 1858696
references: Int J Eat Disord. 1985;4(1):89-99
references: 11540865
references: Gastroenterology. 2007 May;132(6):2087-102
references: 17498505
references: Am J Clin Nutr. 1998 Dec;68(6):1180-6
references: 9846844
references: J Med Chem. 2008 Jan 24;51(2):305-13
references: 18095642
references: Obesity (Silver Spring). 2009 Mar;17(3):494-503
references: 19057523
references: Health Aff (Millwood). 2009 Sep-Oct;28(5):w822-31
references: 19635784
references: Appetite. 1988 Dec;11(3):215-28
references: 3250335
references: Gastroenterol Clin North Am. 2010 Mar;39(1):69-79
references: 20202580
references: Lancet. 1989 Nov 11;2(8672):1142-5
references: 2572857
references: N Engl J Med. 2010 Sep 2;363(10):905-17
references: 20818901
references: JAMA. 2010 Jan 20;303(3):235-41
references: 20071471
references: J Neurosci. 1998 Jul 15;18(14):5537-44
references: 9651234
references: Psychopharmacology (Berl). 1999 Apr;143(3):309-14
references: 10353435
references: J Pharmacol Exp Ther. 2008 May;325(2):577-87
references: 18252809
references: N Engl J Med. 2007 Jan 4;356(1):6-9
references: 17202450
references: Neuropharmacology. 2001 Aug;41(2):200-9
references: 11489456
references: Pharmacol Ther. 2006 Sep;111(3):674-706
references: 16960982
references: Int J Obes Relat Metab Disord. 1998 Aug;22 Suppl 1:S18-28; discussion S29
references: 9758240
references: Cochrane Database Syst Rev. 2003;(4):CD004094
references: 14584004
references: Nature. 1997 Jan 9;385(6612):165-8
references: 8990120
references: Clin Neuropharmacol. 1988;11 Suppl 1:S121-34
references: 3180107
references: Am J Clin Nutr. 2009 Jun;89(6):1723-8
references: 19369382
references: N Engl J Med. 2005 Nov 17;353(20):2111-20
references: 16291981
references: Psychopharmacology (Berl). 1979 Nov;66(2):159-65
references: 119258
references: Endocrinology. 2008 Mar;149(3):1323-8
references: 18039773
references: Am J Pathol. 2002 Dec;161(6):2209-18
references: 12466135
references: Obes Res. 1998 Jan;6(1):1-11
references: 9526964
references: Int J Obes. 1990 Apr;14(4):361-72
references: 2361813
references: Int J Obes Relat Metab Disord. 1994 Mar;18(3):129-35
references: 8186809
references: N Engl J Med. 1997 Aug 28;337(9):581-8
references: 9271479
references: J Clin Endocrinol Metab. 2011 Mar;96(3):837-45
references: 21190985
references: Mol Pharmacol. 2000 Jan;57(1):75-81
references: 10617681
references: Int J Obes Relat Metab Disord. 2003 Jun;27(6):693-700
references: 12833113
references: Int J Obes Relat Metab Disord. 2002 Feb;26(2):262-73
references: 11850760
references: Int J Obes Relat Metab Disord. 1999 Oct;23(10):1016-24
references: 10557021
references: Psychopharmacology (Berl). 1994 Sep;116(1):120-2
references: 7862925
references: Expert Opin Drug Saf. 2009 May;8(3):317-29
references: 19505264
references: Psychopharmacology (Berl). 1992;107(2-3):359-64
references: 1615137
references: Pharmacol Ther. 1998 Sep;79(3):231-57
references: 9776378
references: Int J Obes. 1990 Mar;14(3):219-33
references: 2187822
references: Nature. 1995 Apr 6;374(6522):542-6
references: 7700379
references: Psychopharmacology (Berl). 1997 Oct;133(3):309-12
references: 9361339
references: Clin Pharmacol Ther. 1992 May;51(5):608-14
references: 1587075
references: Eur J Pharmacol. 1993 Sep 21;242(1):83-90
references: 8223940
references: Int J Obes. 1977;1(1):15-42
references: 361584
references: Int J Obes. 1991 Mar;15(3):237-42
references: 1646182
references: J Physiol. 2009 Jan 15;587(1):49-60
references: 19029184
references: Pharmacol Biochem Behav. 1996 Aug;54(4):745-51
references: 8853199
references: N Engl J Med. 2010 Jul 15;363(3):245-56
references: 20647200